|
Mo Heidaran PhD
Head of Regulatory and Translational Strategy
GC Therapeutics
USA
|
Dr. (Mo)hammad Heidaran is currently Head of Translational and Regulatory Strategy at GCTx (GC Therapeutics). He is a recognized expert in the development of cell and gene therapies for rare diseases with more than 9 years of experience at the FDA’s Center for Biologics Evaluation and Research (CBER), 15 years of biotech industrial experience in research, product and intellectual property development working in companies like Celgene, Becton Dickinson and J&J family of companies, and 9 years at the National Cancer Institute where he received his formal training by serving as a Senior Staff Scientist for about 6 years and 3 years as an IRTA fellow studying signal transduction by receptor tyrosine kinases.
Dr. Heidaran holds a Ph.D. in biochemistry with emphasis in molecular and cellular biology from the University of South Carolina, He is founder a new Gordon Research Conference on Synthetic Biology in 2000. He has been an adhoc reviewer and member of editorial boards of several peer reviewed publications. He also holds 25 issued patents and 54 pending patents, and his work has appeared in more than 50 peer-reviewed Speaker 2
scientific publications. He is currently member of International Society of Cell Therapy Legal and Regulatory Affair Committee, and United State Pharmacopeia Bio5 Expert Committee.
Dr. Heidaran holds a Ph.D. in biochemistry with emphasis in molecular and cellular biology from the University of South Carolina, He is founder a new Gordon Research Conference on Synthetic Biology in 2000. He has been an adhoc reviewer and member of editorial boards of several peer reviewed publications. He also holds 25 issued patents and 54 pending patents, and his work has appeared in more than 50 peer-reviewed Speaker 2
scientific publications. He is currently member of International Society of Cell Therapy Legal and Regulatory Affair Committee, and United State Pharmacopeia Bio5 Expert Committee.